Anticancer agent comprising Anti-pd-1 antibody or Anti-pd-l1 antibody

an anticancer agent and anti-pd-1 technology, applied in the field of anticancer agents, can solve the problems of inability to achieve effective anticancer effects, inability to produce effective anticancer effects, and inability to respond to inkt cells greatly, so as to achieve greater production and increase the effect of production
US20100086550A1Inactive Publication Date: 2010-04-08ANTICANCER AGENT COMPRISING ANTI PD 1 ANTIBODY OR ANTI PD L1 ANTIBODY
1 Cites 21 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
ANTICANCER AGENT COMPRISING ANTI PD 1 ANTIBODY OR ANTI PD L1 ANTIBODY
Publication Date
2010-04-08
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1 / PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from Korean Patent Application No.10-2008-0097236, filed Oct. 2, 2008, the entire disclosure of which is incorporated herein by reference in its entirety.TECHNICAL FIELD

[0002] The present invention relates, in general, to an anticancer agent and, more particularly, to an anticancer agent comprising an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to restore the responsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand.BACKGROUND OF THE INVENTION

[0003] Natural killer T (NKT) cells, co-expressing a T cell receptor and NK cell markers, are essential for several aspects of immunity, such as immunomodulation and immunuopotentiation, in various immune diseases including autoimmune diseases, infectious diseases, cancer, etc. NKT cells exist at high levels in the thymus, the liver, and the bone marrow, but at low levels in the spleen,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More